title: Management of Stable Angina - Current Guidelines: A Critical Appraisal.
abstract: Guidelines provide recommendations to improve patient outcomes, but many of the recommendations made for treating patients with stable angina are opinion based rather than evidence based. Risk stratification to predict patients at an increased risk of myocardial infarction (MI) and sudden ischemic death, and selection of patients for possible revascularization, is based on expert opinion. Randomized trials have compared optimal medical therapy to revascularization, after the coronary anatomy was known, and yet routine coronary angiography to exclude left main disease is not recommended. What exactly is optimal antianginal treatment varies considerably from one country's guideline recommendations to another. None of the antianginal drugs reduce mortality or MI and these drugs are equally effective in treating angina pectoris; and yet beta-blockers and calcium channel blockers are recommended as first line therapy. Double and triple therapy with different classes of antianginal drugs is also expert opinion based rather than evidence based. Recommendations to reduce the incidence of MI and sudden death are appropriate; however the use of a potent, high dose statin, is recommended by AHA/ACC and NICE guidelines for all patients with ischemic heart disease, while the European guidelines recommend a target LDL goal in patients with coronary artery disease (CAD). Management of patients with stable angina pectoris with normal coronary arteries remains ambiguous. This short review critically appraises the recommendations for managing patients with stable angina pectoris.
authors.affiliation: Department of Medicine, Cardiovascular Section, University of Oklahoma HSC and VA Medical Center, OU Health Sciences Center, 920 Stanton L Young Boulevard, Room WP3010, Oklahoma City, OK, 73104, USA. udho-thadani@ouhsc.edu.
authors.forename: Udho
authors.initials: U
authors.lastname: Thadani
mesh_terms: D060050:Angina, Stable / Q000188:drug therapy* / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D011379:Prognosis
chemical_list: D002317:Cardiovascular Agents
keywords: ACE inhibitors; Anti-anginals; Current guidelines: critical appraisal; Pharmacotherapy; Stable angina pectoris; Strategies to reduce major adverse cardiac events